

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

05 FEB 10:53 AM 10:53  
**LOBBYING REPORT**

**Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page**

**1. Registrant name**

Organization **ML Strategies, LLC**

**2. Address** ☐ Check if different than previously reported

**701 Pennsylvania Avenue, NW**

**Suite #900**

City **Washington**

State **DC**

Zip Code **20004**

Count

**3. Principal place of business (if different than line 2)**

City

State

Zip Code

Count

State/Zip or Country

**4a. Contact Name**

Prefix Full Name

**Mr. Mark Buse**

**b. Telephone number**

**202.434.7435**

**c. E-mail**

**mbuse@mistrategies.com**

**5. Senate ID #**

**251**

**7. Client Name**

☐ Self

**Pharmaceutical Research & Manufacturers of America**

**6. House ID #**

**33**

**TYPE OF REPORT**

8. Year **2004**

Midyear (January 1-June 30) ☐

OR

Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☒ ⇒ Termination Date **12/01/2004**

11. No Lobby ☐

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

**12. Lobbying Firms**

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☒ ⇒ \$ **40,000**

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

**13. Organizations**

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐

\$10,000 or more ☐ ⇒ \$

**14. REPORTING METHOD.** Check box to indicate accounting method. See instructions for description

- ☐ **Method A.** Reporting amounts using LDA definition
- ☐ **Method B.** Reporting amounts under section 6011 Internal Revenue Code
- ☐ **Method C.** Reporting amounts under section 162(e) Internal Revenue Code

Fo

LD-2DS (Rev. 4/03)

2

Registrant Name ML Strategies, LLCClient Name Pharmaceutical Research & M

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

Issues affecting the pharmaceutical industry.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. Senate  
U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
David	Leiter		
Karen	Knutson		
Mark	Buse		
Neal	Martin		
Patrick	Mara		

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Mark Buse, Vice President of Government Relations 2-11-2005

LD-2DS (R)